Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Core Insights - Aprea Therapeutics, Inc. announced the acceptance of two abstracts for poster presentations at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22 - 26, 2025 [1] Group 1: Clinical Programs - The first abstract focuses on APR-1051, a novel WEE1 inhibitor, detailing early safety and efficacy data from the ACESOT-1051 phase 1 trial [2] - The second abstract presents updated data from the ABOYA-119 trial, which involves ATRN-119, a macrocyclic ATR inhibitor, in patients with advanced solid tumors [2] Group 2: Company Mission and Approach - Aprea's mission is to develop innovative cancer therapies that specifically target cancer cells while minimizing damage to healthy cells, aiming to reduce toxicity associated with conventional treatments [3] - The company is currently developing APR-1051 and ATRN-119 for solid tumor indications, utilizing unique vulnerabilities in cancer cell mutations [3]